sorrento therapeutics lawsuit

on September 24 | in Uncategorized | by | with No Comments

Sorrento Therapeutics stock issued the following: On August 11, 2020, it was reported that an organization calling itself “Hindenburg Research” published claims regarding one of Sorrento’s COVID-19 diagnostic products. We have no business relationship with any company whose stock is mentioned in this article. It says SmartPharm’s Gene Mab platform enables intramuscular delivery of low-immunogenic DNA plasmid-encoded with a therapeutic antibody for long-lasting expression.

As the technology could potentially be applied to DNA, RNA, epigenetic markers and proteins for additional clinical applications such as oncology, the analyst is looking forward to the completion of the preeclampsia verification in Q4 2020 and a possible 2H21 launch. The shorts in collusion with the media are able to manipulate Sorrento Therapeutics stock to profit at the expense of shareholders.

Here are nine large-cap dividend stocks to buy that offer generous -- and more importantly, sustainable -- dividends. spam. NBC 7 reached out to Sorrento Therapeutics for a response to the allegations in the lawsuit but had not heard back as of Friday evening. The company plans to accelerate the development of multiple candidates for in vivo gene-encoded expression of Sorrento antibodies, starting with COVID-19 “cure” STI-1499. $SRNE is up ~120%, adding ~$2.2B in market cap on relentless CNBC hype of its COVID spit test that it bought from Columbia for just $5m + royalties.
In the second half of March, volumes were down 50% compared to the first half of the month, and TCMD’s patient volumes in April and May remained challenged. Shares of Nikola Corp. tumbled 9.3% in premarket trading Thursday, after Wedbush analyst Dan Ives turned bearish on the electric truck maker, saying he now believes the downside risks outweigh any positives. Our alerts consist of Nasdaq, NYSE and high quality OTC companies that are capable of delivering outsized gains to you today, not a year from now.

The Only Man Who Turned $7 into $1 million?

Accenture shares were lower on Thursday after the consulting, technology and outsourcing service provider missed Wall Street's earnings expectations. One of the simplest ways to ensure you're investing in stable companies is to pick large-cap stocks that dominate their markets. Find answers to all of your fixed income questions in our latest FAQ series. as a result of the foregoing, Defendants’ positive statements about the Company’s business operations, and prospects were materially misleading and/or lacked a reasonable basis.

With 3 Buy ratings and 1 Hold, the word on the Street is that TCMD is a Strong Buy. (To watch Furlong’s track record, click here)In general, other analysts are on the same page.
Sorrento is also considering legal action. That day the company's stocks rose sharply, representing an about 281% increase from the day prior, the lawsuit said. “We are encouraged by the recovery in late Q2 2020 with 75,000 accessioned tests (~79,000 in Q1 2020), driven by noninvasive prenatal testing (NIPT) and carrier screening,” the analyst noted.

We spoke with a senior administration official at Columbia who completely debunked the test, telling us: pic.twitter.com/vDzWk06uhE, — Hindenburg Research (@HindenburgRes) August 11, 2020. For over five years, we have provided a free service to a countless number of traders featuring only the best in the microcap arena.

Sorrento will collaborate with law enforcement and regulators to ensure that any criminal activity is investigated and rectified. Thank you for your feedback.

Sorrento has secured manufacturing capacity to support the production of up to five million test kits per month. Several days later, stock investment publications began expressing doubts about the company's claims, which led Sorrento's stock to begin dropping. Expect a 1 to 2-week decline into the next 6-month low.